Anna C. Bettini

Bergamo, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 34 publications

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist

Published: February 11, 2026

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non-small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial-HYPERBOLIC Study.

Journal: Clinical lung cancer

Published: January 11, 2026

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Journal: Cancer

Published: December 16, 2025

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.

Journal: Frontiers in oncology

Published: October 13, 2025

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 16, 2025

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 02, 2025

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: June 03, 2024

Final Results of GERDA on the Two-Neutrino Double-β Decay Half-Life of ^{76}Ge.

Final Results of GERDA on the Two-Neutrino Double-β Decay Half-Life of ^{76}Ge.

Journal: Physical review letters

Published: May 13, 2023

Erratum: First Search for Bosonic Superweakly Interacting Massive Particles with Masses up to 1 MeV/c^{2} with GERDA [Phys. Rev. Lett. 125, 011801 (2020)].

Erratum: First Search for Bosonic Superweakly Interacting Massive Particles with Masses up to 1 MeV/c^{2} with GERDA [Phys. Rev. Lett. 125, 011801 (2020)].

Journal: Physical review letters

Published: June 27, 2022

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.

A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: October 30, 2021

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.

SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study.

Journal: Journal for immunotherapy of cancer

Published: January 06, 2021

Showing 1-12 of 34

Last Updated: 09/26/2026